Data from Alexion's gMG portfolio demonstrate reduced oral corticosteroid burden in adults treated with Soliris or Ultomiris, with further reductions observed in patients transitioning from Soliris to Ultomiris.
Phase 3 MINT trial data indicates inebilizumab significantly improves Myasthenia Gravis Activities of Daily Living (MG-ADL) scores compared to placebo.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.